CYP19A1 and breast cancer: Therefore, while ER inhibitors (e.g., tamoxifen) are preferentially given in premenopausal women with ER+ HBC, aromatase inhibitors are used for the treatment of postmenopausal patients with ER+ breast cancer (103).